AstraZeneca Plc reported higher-than-expected profit, buoyed by blockbuster cancer medicines, as focus turns to the company’s ...

July 27 (Reuters) - AstraZeneca topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand ...

The approval opens a big market for camizestrant as U.S. regulators continue to review the company’s application there.

AstraZeneca received EU approval for Etcamah (camizestrant) in combination with CDK4/6 inhibitors for ER-positive, ...

By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...

Shares in AstraZeneca fell 4% during the second quarter, and deepened their losses in July after the company said its Wainua drug failed to reduce deaths from a heart condition in a late-stage ...

EMA committee recommends approval of AstraZeneca & Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment for patients with HER2-positive metastatic breast cancer: Camb ...

Concerns mounted after the failure of Wainua, an approved treatment for rare neurological disorder ATTR-CM, in a Phase III ...

AstraZeneca has secured exclusive global rights to Dizal's Zegfrovy (sunvozertinib) through a new licensing agreement.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill ...

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

AstraZeneca and Andrews introduce SCREEN, a limited-edition t-shirt designed to spark conversation and inspire action on the benefits of early detection. Erin Andrews wearing limited-edition SCREEN ...